Absci

Absci

Biotechnology Research

Vancouver, Washington 12,632 followers

Creating Drugs at the Speed of Ai

About us

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Vancouver, Washington
Type
Public Company
Founded
2011
Specialties
generative AI, synthetic biology, biologics, drug discovery, antibody development, artificial intelligence, pharmaceuticals, and biotechnology

Locations

Employees at Absci

Updates

Similar pages

Browse jobs

Funding

Absci 11 total rounds

Last Round

Post IPO equity

US$ 86.4M

See more info on crunchbase